TGF-β2 inhibitor has gained market exclusivity in the USA for a third aggressive cancer indication The biopharmaceutical company Antisense Pharma GmbH announces that the US Food and Drug Administration (FDA) has granted Orphan Drug designation for its investigational oncology antisense...